Clinical Trials
20 trialsNCT05924997 2024-02-21
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Unknown
NCT05062837 2024-01-23
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Phase 2/3 Unknown
NCT05031949 2023-12-19
CCGLC-003
Tongji Hospital
Phase 1 Unknown
NCT04559607 2023-12-18
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Phase NA Unknown
NCT04930315 2023-06-13
CAPT
Zhejiang University
Phase 2 Unknown
NCT04443309 2023-03-29
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05048017 2023-03-29
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05171309 2021-12-28
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05135364 2021-11-26
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT04724226 2021-09-05
C-couple
Sun Yat-sen University
Phase 2 Unknown
NCT04479527 2021-01-14
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04297202 2020-08-07
HCC-009
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04035876 2019-07-29
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Zhejiang University
Phase 1/2 Unknown
NCT04014101 2019-07-11
SHR-1210
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03914352 2019-04-16
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Cancer Hospital of Guangxi Medical University
Phase NA Unknown
NCT03793725 2019-01-04
HZ-T-PD1-APA
Harbin Medical University
Phase 2 Unknown
NCT03722875 2018-12-19
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown